Meiji Pharmaceutical's Negative Net Worth and Losses
First written in FY2022. 2 of 5 entries say "Worsened", first in 2026-10-02. Latest entry: FY2026.
Pharma Foods International moved to the "Worse" side of this theme in 2026, 3 years after the typical company in this theme (2023).
The whole theme swung hardest in 2020: 18 of 46 companies on the "Worse" side.
37 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Key financial information for 明治薬品㈱ included net sales of ¥16,744 million, ordinary profit of ¥2,112 million, net profit of ¥1,938 million and net assets of negative ¥2,404 million.」
Although 明治薬品 reported a profit, net assets deteriorated from a positive amount in the previous fiscal year to a capital deficiency of ¥2,404 million. - 2026-10-02WorsenedGeneral Meetings of Shareholders
「Valuation loss on shares of affiliated companies ¥422 million」
A ¥422 million valuation loss on shares of affiliated companies, including Meiji Pharmaceutical, was recorded. The valuation of affiliated-company shares based on their underlying value and earnings forecasts was identified as a significant estimate. - FY2024Maintained profitability, but lower profitAnnual report
「For 明治薬品㈱, the ratio of sales (excluding intercompany sales) to consolidated net sales exceeds 10%. Key financial information: (1) Net sales: ¥14,151 million; (2) Ordinary income: ¥531 million; (3) Net income: ¥153 million; (4) Net assets: ¥444 million」
明治薬品 maintained net assets of ¥444 million after emerging from negative net assets, while ordinary income declined from ¥1,154 million in the previous fiscal year to ¥531 million and net income declined from ¥1,309 million to ¥153 million. - FY2023MitigatedAnnual report
「Key financial information: (1) Revenue: ¥14,108 million; (2) Ordinary profit: ¥1,154 million; (3) Net income: ¥1,309 million; (4) Net assets: ¥279 million.」
For 明治薬品, which had disclosed an ordinary loss, a net loss and negative net assets in the previous fiscal year, the current fiscal year resulted in ordinary profit of ¥1,154 million, net income of ¥1,309 million and net assets of ¥279 million. - FY2022MaterialisedAnnual report
「明治薬品㈱ accounts for more than 10% of consolidated revenue, excluding intercompany revenue. Key financial information: (1) Revenue: ¥8,923 million; (2) Ordinary loss: ¥3,313 million; (3) Net loss: ¥3,355 million; (4) Net assets: negative ¥1,036 million.」
For 明治薬品, which became a consolidated subsidiary, an ordinary loss, a net loss and negative net assets of ¥1,036 million were disclosed.